AUTHORS
Qingsong Yin, PhD, Hao Ai2, Wenli Zuo3, Hongfei Wu4, Zhengrong Liu5, Qian Wang6, Zhanfang Wang7, Yuqing Chen8, Wenyong Li9, Hongyan Ma10, Yi Wu11, Shuxia Guo12
AFFILIATIONS
1 The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2 The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
3 The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
4 The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
5 Anyang City People's Hospital, Anyang, China
6 The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
7 First People's Hospital of Pingdingshan City, Pingdingshan, China
8 Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, China
9 Jiaozuo People's Hospital, Jiaozuo, China
10 The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
11 Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, China
12 Zhengzhou People's Hospital, Zhengzhou, China
ABSTRACT
Background and Aim
Blinatumomab has significantly improved survival in patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). More recently, it has been incorporated into frontline therapy for BCP-ALL, enhancing treatment efficacy. Although current guidelines recommend a 28-day infusion cycle, emerging evidence suggests that a 14-day short-course regimen yields comparable response rates and survival outcomes while offering improved safety and lower costs. To improve outcomes in adults with newly diagnosed BCP-ALL, we prospectively evaluated the efficacy and safety of short-course blinatumomab combined with reduced-dose chemotherapy.
Methods
This prospective, single-arm, multicenter phase II study (ChiCTR2600126853) enrolled patients aged 18–70 years with newly diagnosed BCP-ALL. To enhance the efficacy of blinatumomab and reduce treatment-related toxicities, a reduced-dose chemotherapy (RDC) regimen was administered prior to blinatumomab. Induction consisted of RDC: Idarubicin 5 mg/m²/day on day 1; Vincristine 1.4 mg/m²/day on day 1 (maximum single dose 2 mg); dexamethasone 9 mg/m²/day on days 1–7; and pegaspargase 2500 U/m² on day 3. Bone marrow aspiration was performed on day 14 of induction. Subsequently, all patients received a 2-week blinatumomab induction: 9 µg on days 1–4/7 of the first week, followed by 28 µg/day thereafter. Philadelphia chromosome (Ph)-positive patients concurrently received a second- or third-generation BCR-ABL tyrosine kinase inhibitor. Consolidation comprised 5–7 cycles of high-dose chemotherapy (Hyper-CVAD-P/MA regimen), with a 2-week blinatumomab course administered during the third and fifth cycles. Maintenance therapy consisted of the POMP regimen (Prednisone, Vincristine, 6-Mercaptopurine, and Methotrexate) for 2 years, with a 2-week course of blinatumomab at the start of each year. Patients who failed to achieve composite complete remission (CRc) after the initial 2-week blinatumomab induction were withdrawn from the study. The primary endpoint was the measurable residual disease (MRD) negativity rate by flow cytometry (FCM) after the first 2-week blinatumomab.
Results
From September 2024 to June 2026, 40 patients (median age 41 years; range 18–68) were enrolled across seven centers, including 20 with Ph-positive and 20 with Ph-negative ALL. Twenty-two patients (55%) were male, and 18 (45%) were female. The most frequent mutation was IKZF1(30%), and one patient harbored an IKZF1plus alteration. After RDC, 65% (26/40) of patients achieved CRc, and 27.0% (10/37 evaluable) attained MRD negativity. Following 2 weeks of blinatumomab, all 40 patients (100%) achieved CR, and 95% (38/40) became MRD negative, representing significant improvements compared with pre-blinatumomab rates (both P?<?0.001). Furthermore, the complete molecular remission (CMR) rate in Ph-positive patients increased substantially from 10% before blinatumomab to 70% after treatment (P?<?0.001). Of the 14 patients who did not achieve CRc after RDC, 11 were Ph-negative (including 6 classified as Ph-like BCP-ALL) and 3 were Ph-positive. After 2 weeks of blinatumomab, 5 of the 6 Ph-like BCP-ALL patients achieved CRc with MRD negativity; 4 of the remaining 5 Ph-negative patients also achieved CRc with MRD negativity; and 2 of 3 Ph-positive patients achieved CMR. With a median follow-up of 11.9 months, median PFS and OS were not reached. The estimated 18-month progression-free survival (PFS) and overall survival (OS) rates were both 94.08% (95% CI, 86.36%–100.00%). The estimated 24-month PFS and OS rates were 78.40% (95% CI, 54.26%–100.00%) and 94.08% (95% CI, 86.36%–100.00%), respectively. No treatment-related mortality was observed. Grade ≥3 hematologic adverse events (AE) included neutropenia (50%) and thrombocytopenia (40%). Grade ≥3 non-hematologic AEs included infection (17.5%). Immune effector cell-associated neurotoxicity syndrome (ICANS) was limited, occurring in 2.5% of patients (all Grade 1). Cytokine release syndrome (CRS) occurred in 47.5% of patients, with Grade ≥3 CRS in one patient (2.5%).
Conclusions
These findings confirm that RDC followed by blinatumomab is an effective and well-tolerated induction regimen for newly diagnosed BCP-ALL, regardless of poor-risk features. This supports a paradigm shift toward less intensive, more targeted therapeutic approaches.
Fundings
Supported by Henan Clinical Research-oriented Doctor Program (HNCRD202510) and (244200510008).
DISCLOSURES
Qingsong Yin, PhD: No relevant conflicts of interest to declare.